SB465: Classifying xylazine as a schedule III controlled drug.
Engrossed
Senate
Summary
Classifying xylazine as a schedule III controlled drug.
Sponsors
William Gannon
R - SD-023
Primary
Daryl Abbas
R - SD-022
Co-sponsor
Regina Birdsell
R - SD-019
Co-sponsor
Sharon Carson
R - SD-014
Co-sponsor
David Rochefort
R - SD-001
Co-sponsor
Mark McConkey
R - SD-003
Co-sponsor
Lilli Walsh
R - HD-15-ROC
Co-sponsor
Michael Vose
R - HD-05-ROC
Co-sponsor
Terry Roy
R - HD-31-ROC
Co-sponsor
Jennifer Rhodes
R - HD-17-CHE
Co-sponsor
History
- 2025-11-21 Introduced 01/07/2026 and Referred to Judiciary; Senate Journal 1
- 2026-02-05 Hearing: 02/10/2026, Room 100, State House, 01:30 pm; Senate Calendar 5A
- 2026-02-20 Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; Consent Calendar; Senate Calendar 8
- 2026-02-24 Committee Amendment # 2026-0842s, Amendment Adopted, Voice Vote; 03/05/2026; Senate Journal 5
- 2026-02-24 Ought to Pass with Amendment #2026-0842s, Motion Adopted, Voice Vote; OT3rdg; 03/05/2026; Senate Journal 5
- 2026-03-16 Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture House Journal 8
- 2026-03-18 Public Hearing: 03/31/2026 01:30 pm GP 153
- 2026-04-01 Full Committee Work Session: 04/07/2026 01:00 pm GP 153
- 2026-04-08 Executive Session: 04/14/2026 01:00 pm GP 153
- 2026-04-15 Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; Regular Calendar)
- 2026-04-15 Minority Committee Report: Ought to Pass
Committee Referrals
2025-11-21
Judiciary
Senate
2026-03-16
Environment and Agriculture
House
Calendar Events
Past Events (5)
2026-02-10
Hearing - Room 100, State House
2026-02-10
Hearing - Room 100, State House
2026-03-31
Hearing - GP 153
2026-04-07
Hearing - GP 153
2026-04-14
Hearing - GP 153